https://ir.soligenix.com/ https://ir.soligenix.com/2026-06-08-Soligenix-Applying-for-Vaccine-Development-Funding-for-Bundibugyo-Ebola-Vaccine Mon, 08 Jun 2026 07:30:00 -0400 https://ir.soligenix.com/2026-06-08-Soligenix-Applying-for-Vaccine-Development-Funding-for-Bundibugyo-Ebola-Vaccine https://ir.soligenix.com/2026-05-26-Suitability-of-Vaccine-Platform-for-Bundibugyo-Virus,-Cause-of-the-Ebola-Outbreak-in-Congo Tue, 26 May 2026 07:30:00 -0400 https://ir.soligenix.com/2026-05-26-Suitability-of-Vaccine-Platform-for-Bundibugyo-Virus,-Cause-of-the-Ebola-Outbreak-in-Congo https://ir.soligenix.com/2026-05-08-Soligenix-Announces-Recent-Updates-and-First-Quarter-2026-Financial-Results Fri, 08 May 2026 07:30:00 -0400 https://ir.soligenix.com/2026-05-08-Soligenix-Announces-Recent-Updates-and-First-Quarter-2026-Financial-Results https://ir.soligenix.com/2026-04-28-Soligenix-Announces-Interim-Results-from-the-Phase-3-FLASH2-Trial-Evaluating-HyBryte-TM-in-Treatment-of-Cutaneous-T-Cell-Lymphoma Tue, 28 Apr 2026 07:30:00 -0400 https://ir.soligenix.com/2026-04-28-Soligenix-Announces-Interim-Results-from-the-Phase-3-FLASH2-Trial-Evaluating-HyBryte-TM-in-Treatment-of-Cutaneous-T-Cell-Lymphoma https://ir.soligenix.com/2026-04-02-Positive-Clinical-Results-from-HyBryte-TM-Comparative-Study-Evaluating-HyBryte-TM-Against-Valchlor-R-in-the-Treatment-of-Cutaneous-T-Cell-Lymphoma-Published-in-Oncology-and-Therapy Thu, 02 Apr 2026 07:30:00 -0400 https://ir.soligenix.com/2026-04-02-Positive-Clinical-Results-from-HyBryte-TM-Comparative-Study-Evaluating-HyBryte-TM-Against-Valchlor-R-in-the-Treatment-of-Cutaneous-T-Cell-Lymphoma-Published-in-Oncology-and-Therapy